Hepatitis B immune globulin

Shahid Habib; Obaid S. Shaikh

doi:10.1358/dot.2007.43.6.1050792

Hepatitis B immune globulin

Shahid Habib, Obaid S. Shaikh

Medicine

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Hepatitis B immune globulin (HBIG) is a purified solution of human immunoglobulin that has high titers of antibody to hepatitis B surface antigen (anti-HBs). It is derived from plasma donated by individuals immune to hepatitis B viral infection. HBIG is widely administered to confer passive prophylactic immunity against the hepatitis B virus because of the ability of anti-HBs to neutralize hepatitis B virions. However, it is not indicated for the treatment of acute or chronic hepatitis B. The use of HBIG is recommended in the following clinical situations: i) Acute exposure to blood and secretions containing hepatitis B surface antigen (HBsAg); ii) sexual contact with HBsAg-positive persons; iii) household exposure to persons with acute hepatitis B; iv) perinatal exposure of infants born to HBsAg-positive mothers; v) liver transplantation.

Original language	English (US)
Pages (from-to)	379-394
Number of pages	16
Journal	Drugs of Today
Volume	43
Issue number	6
DOIs	https://doi.org/10.1358/dot.2007.43.6.1050792
State	Published - Jun 2007

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dot.2007.43.6.1050792

Cite this

@article{7e33b72ce4fb413da70efae1b423ed25,

title = "Hepatitis B immune globulin",

abstract = "Hepatitis B immune globulin (HBIG) is a purified solution of human immunoglobulin that has high titers of antibody to hepatitis B surface antigen (anti-HBs). It is derived from plasma donated by individuals immune to hepatitis B viral infection. HBIG is widely administered to confer passive prophylactic immunity against the hepatitis B virus because of the ability of anti-HBs to neutralize hepatitis B virions. However, it is not indicated for the treatment of acute or chronic hepatitis B. The use of HBIG is recommended in the following clinical situations: i) Acute exposure to blood and secretions containing hepatitis B surface antigen (HBsAg); ii) sexual contact with HBsAg-positive persons; iii) household exposure to persons with acute hepatitis B; iv) perinatal exposure of infants born to HBsAg-positive mothers; v) liver transplantation.",

author = "Shahid Habib and Shaikh, {Obaid S.}",

year = "2007",

month = jun,

doi = "10.1358/dot.2007.43.6.1050792",

language = "English (US)",

volume = "43",

pages = "379--394",

journal = "Drugs of Today",

issn = "1699-3993",

publisher = "Prous Science",

number = "6",

}

TY - JOUR

T1 - Hepatitis B immune globulin

AU - Habib, Shahid

AU - Shaikh, Obaid S.

PY - 2007/6

Y1 - 2007/6

N2 - Hepatitis B immune globulin (HBIG) is a purified solution of human immunoglobulin that has high titers of antibody to hepatitis B surface antigen (anti-HBs). It is derived from plasma donated by individuals immune to hepatitis B viral infection. HBIG is widely administered to confer passive prophylactic immunity against the hepatitis B virus because of the ability of anti-HBs to neutralize hepatitis B virions. However, it is not indicated for the treatment of acute or chronic hepatitis B. The use of HBIG is recommended in the following clinical situations: i) Acute exposure to blood and secretions containing hepatitis B surface antigen (HBsAg); ii) sexual contact with HBsAg-positive persons; iii) household exposure to persons with acute hepatitis B; iv) perinatal exposure of infants born to HBsAg-positive mothers; v) liver transplantation.

AB - Hepatitis B immune globulin (HBIG) is a purified solution of human immunoglobulin that has high titers of antibody to hepatitis B surface antigen (anti-HBs). It is derived from plasma donated by individuals immune to hepatitis B viral infection. HBIG is widely administered to confer passive prophylactic immunity against the hepatitis B virus because of the ability of anti-HBs to neutralize hepatitis B virions. However, it is not indicated for the treatment of acute or chronic hepatitis B. The use of HBIG is recommended in the following clinical situations: i) Acute exposure to blood and secretions containing hepatitis B surface antigen (HBsAg); ii) sexual contact with HBsAg-positive persons; iii) household exposure to persons with acute hepatitis B; iv) perinatal exposure of infants born to HBsAg-positive mothers; v) liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=34547761311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547761311&partnerID=8YFLogxK

U2 - 10.1358/dot.2007.43.6.1050792

DO - 10.1358/dot.2007.43.6.1050792

M3 - Review article

C2 - 17612709

AN - SCOPUS:34547761311

SN - 1699-3993

VL - 43

SP - 379

EP - 394

JO - Drugs of Today

JF - Drugs of Today

IS - 6

ER -

Hepatitis B immune globulin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this